{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:03:00Z","timestamp":1789873380339,"version":"4.0.1"},"reference-count":193,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.pharmthera.2020.107552","type":"journal-article","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T21:25:21Z","timestamp":1587072321000},"page":"107552","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["An overview on anti-tubulin agents for the treatment of lymphoma patients"],"prefix":"10.1016","volume":"211","author":[{"given":"Marilia","family":"Barreca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Stathis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Barraja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bertoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.pharmthera.2020.107552_bb0005","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1158\/1078-0432.CCR-16-0772","article-title":"Phase I study of the anti-CD22 antibody-drug conjugate Pinatuzumab Vedotin with\/without rituximab in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"23","author":"Advani","year":"2017","journal-title":"Clinical Cancer Research"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107552_bb0010","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1200\/JCO.2006.08.7304","article-title":"Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas","volume":"25","author":"Aghajanian","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107552_bb0015","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.clml.2018.08.018","article-title":"A phase I study to assess the safety and pharmacokinetics of single-agent Lorvotuzumab Mertansine (IMGN901) in patients with relapsed and\/or refractory CD-56-positive multiple myeloma","volume":"19","author":"Ailawadhi","year":"2019","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107552_bb0020","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1158\/1078-0432.CCR-08-2808","article-title":"Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin\u2019s lymphoma. [comparative study]","volume":"15","author":"Al-Katib","year":"2009","journal-title":"Clinical Cancer Research"},{"issue":"13","key":"10.1016\/j.pharmthera.2020.107552_bb0025","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2174\/1381612053764715","article-title":"Recent developments in the chemical biology of epothilones","volume":"11","author":"Altmann","year":"2005","journal-title":"Current Pharmaceutical Design"},{"issue":"13 Supplement","key":"10.1016\/j.pharmthera.2020.107552_bb0030","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1158\/1538-7445.AM2018-880","article-title":"Abstract 880: Anti-tubulin antibody drug conjugates potentiate venetoclax activity in non-Hodgkin lymphoma by targeting MCL-1","volume":"78","author":"Amin","year":"2018","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107552_bb0035","series-title":"Proceedings of the 109th annual AACR meeting","article-title":"Development of novel preclinical models of secondary resistance to the anti-CD37 antibody drug conjugate (ADC) IMGN529\/DEBIO1562 in diffuse large B-cell lymphoma (DLBCL)","author":"Arribas","year":"2018"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107552_bb0040","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/0006-2952(90)90613-P","article-title":"Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain","volume":"39","author":"Bai","year":"1990","journal-title":"Biochemical Pharmacology"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107552_bb0045","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/oxfordjournals.annonc.a010802","article-title":"Activity of single agent vinorelbine in pretreated non-Hodgkin\u2019s lymphoma","volume":"7","author":"Balzarotti","year":"1996","journal-title":"Annals of Oncology"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107552_bb0050","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/annonc\/mdm090","article-title":"Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin\u2019s lymphoma: CALGB 59804","volume":"18","author":"Bartlett","year":"2007","journal-title":"Annals of Oncology"},{"issue":"21","key":"10.1016\/j.pharmthera.2020.107552_bb0055","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1200\/JCO.18.01994","article-title":"Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: Clinical outcomes of the phase III intergroup trial Alliance\/CALGB 50303","volume":"37","author":"Bartlett","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107552_bb0060","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/bcp.13126","article-title":"Microtubule destabilising agents: Far more than just antimitotic anticancer drugs","volume":"83","author":"Bates","year":"2017","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107552_bb0065","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1158\/1535-7163.MCT-12-1197","article-title":"Vinblastine rapidly induces NOXA and acutely sensitizes primary chronic lymphocytic leukemia cells to ABT-737","volume":"12","author":"Bates","year":"2013","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.pharmthera.2020.107552_bb0070","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-3-642-81488-4_13","article-title":"Vindesine: a new vinca alkaloid","volume":"74","author":"Bayssas","year":"1980","journal-title":"Recent Results in Cancer Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107552_bb0075","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0014-5793(77)80075-6","article-title":"Maytansine binding to the vinblastine sites of tubulin","volume":"75","author":"Bhattacharyya","year":"1977","journal-title":"FEBS Letters"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107552_bb0080","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1158\/1535-7163.MCT-06-0242","article-title":"Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton","volume":"5","author":"Bijman","year":"2006","journal-title":"Molecular Cancer Therapeutics"},{"issue":"13","key":"10.1016\/j.pharmthera.2020.107552_bb0085","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2174\/1381612013397465","article-title":"Preclinical evaluation of new taxoids","volume":"7","author":"Bissery","year":"2001","journal-title":"Current Pharmaceutical Design"},{"issue":"20","key":"10.1016\/j.pharmthera.2020.107552_bb0090","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.1158\/1078-0432.CCR-11-0485","article-title":"SAR3419: An anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. [review]","volume":"17","author":"Blanc","year":"2011","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107552_bb0095","doi-asserted-by":"crossref","first-page":"14683","DOI":"10.1038\/ncomms14683","article-title":"Deconvolution of Buparlisib\u2019s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention","volume":"8","author":"Bohnacker","year":"2017","journal-title":"Nature Communications"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107552_bb0100","first-page":"2325","article-title":"Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action","volume":"55","author":"Bollag","year":"1995","journal-title":"Cancer Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107552_bb0105","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s002800050396","article-title":"Vincristine-induced dermal toxicity is significantly reduced when the drug is given in liposomes","volume":"37","author":"Boman","year":"1996","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107552_bb0110","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7","article-title":"Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP","volume":"36","author":"Bonadonna","year":"1975","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107552_bb0115","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1046\/j.1365-2141.1998.00989.x","article-title":"Ifosfamide and vinorelbine: An active regimen for patients with relapsed or refractory Hodgkin\u2019s disease","volume":"103","author":"Bonfante","year":"1998","journal-title":"British Journal of Haematology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107552_bb0120","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3892\/mco.2016.1090","article-title":"Complete response to azacitidine priming and nab-paclitaxel in non-Hodgkin lymphoma resistant to biochemotherapy","volume":"6","author":"Bowen","year":"2017","journal-title":"Molecular and Clinical Oncology"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107552_bb0125","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1200\/JCO.1997.15.10.3275","article-title":"Phase II trial of docetaxel in non-Hodgkin\u2019s lymphomas: A study of the cancer and leukemia group B","volume":"15","author":"Budman","year":"1997","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107552_bb0130","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/oxfordjournals.annonc.a058466","article-title":"Effective salvage chemotherapy in relapsed or refractory non-Hodgkin\u2019s lymphoma","volume":"4","author":"Buzzoni","year":"1993","journal-title":"Annals of Oncology"},{"issue":"21","key":"10.1016\/j.pharmthera.2020.107552_bb0135","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of advanced Hodgkin\u2019s disease with MOPP, ABVD, or MOPP alternating with ABVD","volume":"327","author":"Canellos","year":"1992","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107552_bb0140","first-page":"811","article-title":"Management of patients with malignant lymphoma: A comparative study with cyclophosphamide and vinca alkaloids","volume":"28","author":"Carbone","year":"1968","journal-title":"Cancer Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107552_bb0145","first-page":"502","article-title":"Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin\u2019s lymphomas. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"85","author":"Casasnovas","year":"2000","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107552_bb0150","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1182\/blood-2017-02-766691","article-title":"FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: Final results of a randomized phase 2 study","volume":"130","author":"Casasnovas","year":"2017","journal-title":"Blood"},{"issue":"Pt 2","key":"10.1016\/j.pharmthera.2020.107552_bb0155","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1242\/jcs.98.2.151","article-title":"Kinetochore microtubules shorten by loss of subunits at the kinetochores of prometaphase chromosomes","volume":"98","author":"Cassimeris","year":"1991","journal-title":"Journal of Cell Science"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107552_bb0160","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/j.1875-9114.1983.tb03269.x","article-title":"Pharmacology, clinical efficacy and adverse effects of vindesine sulfate, a new vinca alkaloid","volume":"3","author":"Cersosimo","year":"1983","journal-title":"Pharmacotherapy"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107552_bb0165","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.pharmthera.2020.107552_bb0170","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS7584","article-title":"A randomized, phase 2 trial of denintuzumab mafodotin and RICE vs RICE alone in the treatment of patients (pts) with relapsed\/refractory (r\/r) diffuse large B-cell lymphoma (DLBCL) who are candidates for autologous stem cell transplant (ASCT)","volume":"34","author":"Chen","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107552_bb0175","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/cbdd.12475","article-title":"The unique binding mode of Laulimalide to two tubulin Protofilaments","volume":"86","author":"Churchill","year":"2015","journal-title":"Chemical Biology & Drug Design"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107552_bb0180","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/cncr.27917","article-title":"A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas","volume":"119","author":"Churpek","year":"2013","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107552_bb0185","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/oxfordjournals.annonc.a057673","article-title":"Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: A prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d\u2019Etude des Lymphomes Agressives)","volume":"1","author":"Coiffier","year":"1990","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107552_bb0190","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood.V70.5.1394.1394","article-title":"Intensive chemotherapy in aggressive lymphomas: Updated results of LNH-80 protocol and prognostic factors affecting response and survival","volume":"70","author":"Coiffier","year":"1987","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107552_bb0195","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107552_bb0200","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/bjh.13992","article-title":"A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"173","author":"Coiffier","year":"2016","journal-title":"British Journal of Haematology"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107552_bb0205","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1200\/JCO.2008.20.3778","article-title":"Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin\u2019s disease: A children\u2019s oncology group report","volume":"27","author":"Cole","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107552_bb0210","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"The New England Journal of Medicine"},{"issue":"5 Suppl 14","key":"10.1016\/j.pharmthera.2020.107552_bb0215","first-page":"88","article-title":"CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma","volume":"26","author":"Czuczman","year":"1999","journal-title":"Seminars in Oncology"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107552_bb0220","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1093\/humrep\/dei018","article-title":"Fertility and ovarian function are preserved in women treated with an intensified regimen of cyclophosphamide, adriamycin, vincristine and prednisone (mega-CHOP) for non-Hodgkin lymphoma","volume":"20","author":"Dann","year":"2005","journal-title":"Human Reproduction"},{"issue":"20","key":"10.1016\/j.pharmthera.2020.107552_bb0225","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1182\/blood-2013-05-505685","article-title":"A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies","volume":"122","author":"Deckert","year":"2013","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.pharmthera.2020.107552_bb0230","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s40265-019-01175-0","article-title":"Polatuzumab vedotin: first global approval","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107552_bb0235","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-05-1634","article-title":"Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel","volume":"12","author":"Desai","year":"2006","journal-title":"Clinical Cancer Research"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107552_bb0240","doi-asserted-by":"crossref","first-page":"881","DOI":"10.7326\/0003-4819-73-6-881","article-title":"Combination chemotherapy in the treatment of advanced Hodgkin\u2019s disease","volume":"73","author":"Devita","year":"1970","journal-title":"Annals of Internal Medicine"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107552_bb0245","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/oxfordjournals.annonc.a059010","article-title":"Vinorelbine: An active drug for the management of patients with heavily pretreated Hodgkin\u2019s disease","volume":"5","author":"Devizzi","year":"1994","journal-title":"Annals of Oncology"},{"issue":"34","key":"10.1016\/j.pharmthera.2020.107552_bb0250","first-page":"26265","article-title":"Molecular recognition of taxol by microtubules. Kinetics and thermodynamics of binding of fluorescent taxol derivatives to an exposed site","volume":"275","author":"Diaz","year":"2000","journal-title":"The Journal of Biological Chemistry"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107552_bb0255","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1200\/JCO.1998.16.12.3810","article-title":"BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP\/ABVD in patients with advanced-stage Hodgkin\u2019s lymphoma: Interim report from a trial of the German Hodgkin\u2019s lymphoma study group","volume":"16","author":"Diehl","year":"1998","journal-title":"Journal of Clinical Oncology"},{"issue":"24","key":"10.1016\/j.pharmthera.2020.107552_bb0260","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin\u2019s disease","volume":"348","author":"Diehl","year":"2003","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107552_bb0265","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1021\/bc0502917","article-title":"Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity","volume":"17","author":"Doronina","year":"2006","journal-title":"Bioconjugate Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107552_bb0270","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/sj.onc.1208189","article-title":"Characterization of vinblastine-induced Bcl-xL and Bcl-2 phosphorylation: Evidence for a novel protein kinase and a coordinated phosphorylation\/dephosphorylation cycle associated with apoptosis induction","volume":"24","author":"Du","year":"2005","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107552_bb0275","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/1568011023354452","article-title":"Novel aspects of natural and modified vinca alkaloids","volume":"2","author":"Duflos","year":"2002","journal-title":"Current Medicinal Chemistry. Anti-Cancer Agents"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107552_bb0280","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1021\/acs.jnatprod.7b00359","article-title":"Synthesis and evaluation of Dolastatin 10 analogues containing heteroatoms on the amino acid side chains","volume":"80","author":"Dugal-Tessier","year":"2017","journal-title":"Journal of Natural Products"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107552_bb0285","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.1999.17.3.1061","article-title":"Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport, and cell death","volume":"17","author":"Dumontet","year":"1999","journal-title":"Journal of Clinical Oncology"},{"issue":"23","key":"10.1016\/j.pharmthera.2020.107552_bb0290","doi-asserted-by":"crossref","first-page":"6123","DOI":"10.1182\/blood-2010-02-269811","article-title":"Optimized anti-tumor effects of anthracyclines plus Vinca alkaloids using a novel, mechanism-based application schedule","volume":"118","author":"Ehrhardt","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107552_bb0295","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1208\/s12248-012-9386-x","article-title":"ADME of antibody-maytansinoid conjugates","volume":"14","author":"Erickson","year":"2012","journal-title":"The AAPS Journal"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107552_bb0300","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/oxfordjournals.annonc.a059242","article-title":"The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin\u2019s disease","volume":"6","author":"Ferme","year":"1995","journal-title":"Annals of Oncology"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107552_bb0305","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.3324\/haematol.2010.038109","article-title":"Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA","volume":"96","author":"Fitoussi","year":"2011","journal-title":"Haematologica"},{"issue":"26","key":"10.1016\/j.pharmthera.2020.107552_bb0310","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","article-title":"Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older","volume":"126","author":"Forero-Torres","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107552_bb0315","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"issue":"Suppl. 5","key":"10.1016\/j.pharmthera.2020.107552_bb0320","doi-asserted-by":"crossref","first-page":"v9","DOI":"10.1093\/annonc\/mdm173","article-title":"Novel tubulin-targeting agents: Anticancer activity and pharmacologic profile of epothilones and related analogues","volume":"18","author":"Fumoleau","year":"2007","journal-title":"Annals of Oncology"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107552_bb0325","first-page":"1182","article-title":"EPO-906 (Novartis)","volume":"6","author":"Galmarini","year":"2003","journal-title":"IDrugs"},{"issue":"22, ASH 2016","key":"10.1016\/j.pharmthera.2020.107552_bb0330","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1182\/blood.V128.22.4187.4187","article-title":"Identification of anti-lymphoma biomarkers of response to the anti-CD37 antibody drug conjugate (ADC) IMGN529","volume":"128","author":"Gaudio","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107552_bb0335","article-title":"Targeting CD205 with the antibody drug conjugate MEN1309\/OBT076 is an active new therapeutic strategy in lymphoma models","author":"Gaudio","year":"2020","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107552_bb0340","doi-asserted-by":"crossref","first-page":"560","DOI":"10.7164\/antibiotics.49.560","article-title":"Epothilons a and B: Antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties","volume":"49","author":"Gerth","year":"1996","journal-title":"Journal of Antibiotics (Tokyo)"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107552_bb0345","doi-asserted-by":"crossref","first-page":"41","DOI":"10.7164\/antibiotics.55.41","article-title":"Studies on the biosynthesis of epothilones: Hydroxylation of Epo a and B to epothilones E and F","volume":"55","author":"Gerth","year":"2002","journal-title":"Journal of Antibiotics (Tokyo)"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107552_bb0350","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/10428194.2017.1330954","article-title":"Minimal activity of nanoparticle albumin-bound (nab) paclitaxel in relapsed or refractory lymphomas: Results of a phase-I study","volume":"59","author":"Goyal","year":"2018","journal-title":"Leukemia & Lymphoma"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107552_bb0355","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/bjh.12379","article-title":"High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: Results of the R-NIMP GOELAMS study","volume":"162","author":"Gyan","year":"2013","journal-title":"British Journal of Haematology"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107552_bb0360","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1002\/1097-0142(19940515)73:10<2515::AID-CNCR2820731011>3.0.CO;2-G","article-title":"Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas","volume":"73","author":"Haim","year":"1994","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107552_bb0365","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1080\/10428190400029932","article-title":"R-CHOP-14 in patients with diffuse large B-cell lymphoma: Feasibility and preliminary efficacy","volume":"46","author":"Halaas","year":"2005","journal-title":"Leukemia & Lymphoma"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107552_bb0370","first-page":"229","article-title":"Bcl2 is the guardian of microtubule integrity","volume":"57","author":"Haldar","year":"1997","journal-title":"Cancer Research"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107552_bb0375","first-page":"1609","article-title":"Serine-70 is one of the critical sites for drug-induced Bcl2 phosphorylation in cancer cells","volume":"58","author":"Haldar","year":"1998","journal-title":"Cancer Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107552_bb0380","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1124\/mol.106.027847","article-title":"Synergistic effects of peloruside a and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly","volume":"70","author":"Hamel","year":"2006","journal-title":"Molecular Pharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107552_bb0385","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s10495-013-0928-1","article-title":"Prometaphase arrest-dependent phosphorylation of Bcl-2 and Bim reduces the association of Bcl-2 with Bak or Bim, provoking Bak activation and mitochondrial apoptosis in nocodazole-treated Jurkat T cells","volume":"19","author":"Han","year":"2014","journal-title":"Apoptosis"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107552_bb0390","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/0163-7258(91)90067-V","article-title":"Interactions of colchicine with tubulin","volume":"51","author":"Hastie","year":"1991","journal-title":"Pharmacology & Therapeutics"},{"issue":"4\u20135","key":"10.1016\/j.pharmthera.2020.107552_bb0395","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/hon.2900090411","article-title":"Etoposide, ifosfamide and methotrexate combination chemotherapy in patients with aggressive non-Hodgkin\u2019s lymphoma after failure of the LNH 84 regimen","volume":"9","author":"Herbrecht","year":"1991","journal-title":"Hematological Oncology"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107552_bb0400","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.3324\/haematol.2018.211011","article-title":"The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models","volume":"104","author":"Hicks","year":"2019","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107552_bb0405","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/oxfordjournals.annonc.a010613","article-title":"Paclitaxel in the salvage treatment of Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma","volume":"7","author":"Hopfinger","year":"1996","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107552_bb0410","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/bjh.13388","article-title":"A phase 2 study of bortezomib in combination with ifosfamide\/vinorelbine in paediatric patients and young adults with refractory\/recurrent Hodgkin lymphoma: A Children\u2019s oncology group study","volume":"170","author":"Horton","year":"2015","journal-title":"British Journal of Haematology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107552_bb0415","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.jmb.2008.03.026","article-title":"A unique mode of microtubule stabilization induced by peloruside a","volume":"378","author":"Huzil","year":"2008","journal-title":"Journal of Molecular Biology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107552_bb0420","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjh.13338","article-title":"Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: A randomized phase II study","volume":"169","author":"Ishida","year":"2015","journal-title":"British Journal of Haematology"},{"issue":"13","key":"10.1016\/j.pharmthera.2020.107552_bb0425","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.1021\/ja809842b","article-title":"Total synthesis of vinblastine, vincristine, related natural products, and key structural analogues","volume":"131","author":"Ishikawa","year":"2009","journal-title":"Journal of the American Chemical Society"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107552_bb0430","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/annonc\/mdh093","article-title":"Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: Results of a phase II study","volume":"15","author":"Jermann","year":"2004","journal-title":"Annals of Oncology"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107552_bb0435","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27765","article-title":"Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts","volume":"66","author":"Jones","year":"2019","journal-title":"Pediatric Blood & Cancer"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107552_bb0440","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00280-004-0928-5","article-title":"Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analog","volume":"56","author":"Kamath","year":"2005","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107552_bb0445","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2613.2009.00651.x","article-title":"Microtubule depolymerizing vascular disrupting agents: Novel therapeutic agents for oncology and other pathologies","volume":"90","author":"Kanthou","year":"2009","journal-title":"International Journal of Experimental Pathology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107552_bb0450","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.clml.2013.09.009","article-title":"Phase II study of vincristine sulfate liposome injection (Marqibo) and rituximab for patients with relapsed and refractory diffuse large B-cell lymphoma or mantle cell lymphoma in need of palliative therapy","volume":"14","author":"Kaplan","year":"2014","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.pharmthera.2020.107552_bb0455","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejmech.2014.09.051","article-title":"Recent developments in tubulin polymerization inhibitors: An overview","volume":"87","author":"Kaur","year":"2014","journal-title":"European Journal of Medicinal Chemistry"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107552_bb0460","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/annonc\/mds600","article-title":"Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B)","volume":"24","author":"Ketterer","year":"2013","journal-title":"Annals of Oncology"},{"issue":"47","key":"10.1016\/j.pharmthera.2020.107552_bb0465","doi-asserted-by":"crossref","first-page":"7942","DOI":"10.1002\/anie.200602785","article-title":"Total synthesis and antitumor activity of ZK-EPO: The first fully synthetic epothilone in clinical development","volume":"45","author":"Klar","year":"2006","journal-title":"Angewandte Chemie (International Ed. in English)"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107552_bb0470","first-page":"1292","article-title":"BMS-310705 Bristol-Myers Squibb\/GBF","volume":"5","author":"Kolman","year":"2004","journal-title":"Current Opinion in Investigational Drugs"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107552_bb0475","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1007\/s10637-011-9765-7","article-title":"Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma","volume":"30","author":"Konner","year":"2012","journal-title":"Investigational New Drugs"},{"issue":"4\u20135","key":"10.1016\/j.pharmthera.2020.107552_bb0480","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/hon.2900090407","article-title":"Sequential versus alternating chemotherapy for high grade non-Hodgkin\u2019s lymphomas: A randomized multicentre trial","volume":"9","author":"Koppler","year":"1991","journal-title":"Hematological Oncology"},{"key":"10.1016\/j.pharmthera.2020.107552_bb0485","first-page":"82","article-title":"Resistance to anti-tubulin agents: From vinca alkaloids to epothilones","volume":"2","author":"Krause","year":"2019","journal-title":"Cancer Drug Resistance"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107552_bb0490","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s002800050764","article-title":"Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid","volume":"41","author":"Kruczynski","year":"1998","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107552_bb0495","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1040-8428(01)00183-4","article-title":"Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties","volume":"40","author":"Kruczynski","year":"2001","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107552_bb0500","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1023\/A:1008349209956","article-title":"Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer","volume":"11","author":"Krug","year":"2000","journal-title":"Annals of Oncology"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107552_bb0505","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1021\/ja00759a054","article-title":"Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus","volume":"94","author":"Kupchan","year":"1972","journal-title":"Journal of the American Chemical Society"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107552_bb0510","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/ijc.2910490512","article-title":"P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines","volume":"49","author":"Lai","year":"1991","journal-title":"International Journal of Cancer"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107552_bb0515","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00280-011-1724-7","article-title":"Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors","volume":"69","author":"Lam","year":"2012","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107552_bb0520","first-page":"1429","article-title":"BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy","volume":"7","author":"Lee","year":"2001","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107552_bb0525","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hon.2900070109","article-title":"Lomustine, vindesine and bleomycin (LVB) used in the treatment of relapsed advanced Hodgkin\u2019s disease. A prospective study on behalf of the east of Scotland and Newcastle lymphoma group (ESNLG)","volume":"7","author":"Lennard","year":"1989","journal-title":"Hematological Oncology"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107552_bb0530","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1158\/1535-7163.MCT-12-1173","article-title":"DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma","volume":"12","author":"Li","year":"2013","journal-title":"Molecular Cancer Therapeutics"},{"issue":"17","key":"10.1016\/j.pharmthera.2020.107552_bb0535","doi-asserted-by":"crossref","first-page":"6279","DOI":"10.1016\/j.bmc.2009.07.040","article-title":"Synthesis and biological evaluation of 3,4-diaryl-5-aminoisoxazole derivatives","volume":"17","author":"Liu","year":"2009","journal-title":"Bioorganic & Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107552_bb0540","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0076-6879(00)23362-4","article-title":"Energetics of vinca alkaloid interactions with tubulin","volume":"323","author":"Lobert","year":"2000","journal-title":"Methods in Enzymology"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107552_bb0545","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1080\/10428190600774923","article-title":"Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed\/refractory lymphoma","volume":"47","author":"Lonial","year":"2006","journal-title":"Leukemia & Lymphoma"},{"issue":"26","key":"10.1016\/j.pharmthera.2020.107552_bb0550","doi-asserted-by":"crossref","first-page":"9468","DOI":"10.1021\/jo026460n","article-title":"Synthesis of C-3\u2032 methyl taxotere (docetaxel)","volume":"67","author":"Lucatelli","year":"2002","journal-title":"The Journal of Organic Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107552_bb0555","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10456-009-9134-8","article-title":"A comparative study on the anti-angiogenic effects of DNA-damaging and cytoskeletal-disrupting agents","volume":"12","author":"Mabeta","year":"2009","journal-title":"Angiogenesis"},{"issue":"24","key":"10.1016\/j.pharmthera.2020.107552_bb0560","doi-asserted-by":"crossref","first-page":"10527","DOI":"10.1021\/jm501649k","article-title":"Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications","volume":"57","author":"Maderna","year":"2014","journal-title":"Journal of Medicinal Chemistry"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107552_bb0565","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1200\/JCO.2015.62.4817","article-title":"Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi","volume":"34","author":"Merli","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107552_bb0570","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1158\/1535-7163.MCT-18-0624","article-title":"MEN1309\/OBT076, a first-in-class antibody-drug conjugate targeting CD205 in solid tumors","volume":"18","author":"Merlino","year":"2019","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.pharmthera.2020.107552_bb0575","first-page":"935","article-title":"Side effects of drugs annual","volume":"33","author":"Middleton","year":"2011","journal-title":"Cytotoxic and cytostatic drugs"},{"key":"10.1016\/j.pharmthera.2020.107552_bb0580","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0091-679X(10)95007-3","article-title":"Methods in tubulin proteomics","volume":"95","author":"Miller","year":"2010","journal-title":"Methods in Cell Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107552_bb0585","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM199807023390104","article-title":"Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin\u2019s lymphoma","volume":"339","author":"Miller","year":"1998","journal-title":"The New England Journal of Medicine"},{"issue":"8112","key":"10.1016\/j.pharmthera.2020.107552_bb0590","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(79)92894-0","article-title":"Chemotherapy of localised histiocytic lymphoma","volume":"1","author":"Miller","year":"1979","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107552_bb0595","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1025513106330","article-title":"Microtubules, microtubule-interfering agents and apoptosis","volume":"8","author":"Mollinedo","year":"2003","journal-title":"Apoptosis"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107552_bb0600","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/annonc\/mdi243","article-title":"Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin\u2019s lymphomas","volume":"16","author":"Monfardini","year":"2005","journal-title":"Annals of Oncology"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107552_bb0605","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1007\/s10637-011-9731-4","article-title":"A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin(R)) in patients with advanced solid tumors","volume":"30","author":"Monk","year":"2012","journal-title":"Investigational New Drugs"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107552_bb0610","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S2352-3026(19)30026-2","article-title":"Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: Final results from a phase 2 randomised study (ROMULUS)","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematology"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107552_bb0615","first-page":"1231","article-title":"Vinca alkaloids","volume":"4","author":"Moudi","year":"2013","journal-title":"International Journal of Preventive Medicine"},{"issue":"16","key":"10.1016\/j.pharmthera.2020.107552_bb0620","doi-asserted-by":"crossref","first-page":"8192","DOI":"10.1158\/0008-5472.CAN-06-0748","article-title":"Taxotere-induced inhibition of human endothelial cell migration is a result of heat shock protein 90 degradation","volume":"66","author":"Murtagh","year":"2006","journal-title":"Cancer Research"},{"issue":"5685","key":"10.1016\/j.pharmthera.2020.107552_bb0625","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1126\/science.1099190","article-title":"The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography","volume":"305","author":"Nettles","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2020.107552_bb0630","doi-asserted-by":"crossref","first-page":"45682","DOI":"10.1038\/srep45682","article-title":"Antibody-targeted paclitaxel loaded nanoparticles for the treatment of CD20(+) B-cell lymphoma","volume":"7","author":"Nevala","year":"2017","journal-title":"Scientific Reports"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107552_bb0635","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1139\/o90-197","article-title":"The discovery of the vinca alkaloids--chemotherapeutic agents against cancer","volume":"68","author":"Noble","year":"1990","journal-title":"Biochemistry and Cell Biology"},{"issue":"17","key":"10.1016\/j.pharmthera.2020.107552_bb0640","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1091\/mbc.E14-11-1514","article-title":"Gamma-tubulin complexes in microtubule nucleation and beyond","volume":"26","author":"Oakley","year":"2015","journal-title":"Molecular Biology of the Cell"},{"issue":"6217","key":"10.1016\/j.pharmthera.2020.107552_bb0645","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/338662a0","article-title":"Identification of gamma-tubulin, a new member of the tubulin superfamily encoded by mipA gene of Aspergillus nidulans","volume":"338","author":"Oakley","year":"1989","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107552_bb0650","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2141.2008.07271.x","article-title":"A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma","volume":"143","author":"O\u2019Connor","year":"2008","journal-title":"British Journal of Haematology"},{"issue":"19","key":"10.1016\/j.pharmthera.2020.107552_bb0655","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.1158\/1078-0432.CCR-08-0916","article-title":"Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker","volume":"14","author":"Oflazoglu","year":"2008","journal-title":"Clinical Cancer Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107552_bb0660","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1158\/1078-0432.CCR-09-2069","article-title":"Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate","volume":"16","author":"Okeley","year":"2010","journal-title":"Clinical Cancer Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107552_bb0665","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/0006-291X(82)91080-4","article-title":"Structure-activity study of cytotoxicity and microtubule assembly in vitro by taxol and related taxanes","volume":"105","author":"Parness","year":"1982","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107552_bb0670","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0305-7372(93)90010-O","article-title":"The taxoids: Paclitaxel (Taxol) and docetaxel (Taxotere)","volume":"19","author":"Pazdur","year":"1993","journal-title":"Cancer Treatment Reviews"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107552_bb0675","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1158\/1535-7163.MCT-09-0366","article-title":"Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance","volume":"8","author":"Perez","year":"2009","journal-title":"Molecular Cancer Therapeutics"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107552_bb0680","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1038\/leu.2015.48","article-title":"Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes","volume":"29","author":"Pfeifer","year":"2015","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107552_bb0685","first-page":"1203","volume":"71","author":"Pfreundschuh","year":"1987","journal-title":"Cancer Treatment Reports"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107552_bb0690","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10637-018-0655-0","article-title":"A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma","volume":"37","author":"Phillips","year":"2019","journal-title":"Investigational New Drugs"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107552_bb0695","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2007-01-066704","article-title":"Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma","volume":"110","author":"Polson","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107552_bb0700","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1200\/JCO.1998.16.2.574","article-title":"Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin\u2019s lymphomas: Southwest oncology group trial 9246","volume":"16","author":"Press","year":"1998","journal-title":"Journal of Clinical Oncology"},{"issue":"18","key":"10.1016\/j.pharmthera.2020.107552_bb0705","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"25","key":"10.1016\/j.pharmthera.2020.107552_bb0710","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","article-title":"Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"130","author":"Pro","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107552_bb0715","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1080\/10428190600684999","article-title":"Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin\u2019s lymphoma","volume":"47","author":"Pro","year":"2006","journal-title":"Leukemia & Lymphoma"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107552_bb0720","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/bjh.13273","article-title":"Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA group","volume":"169","author":"Purroy","year":"2015","journal-title":"British Journal of Haematology"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107552_bb0725","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.bcp.2011.01.017","article-title":"Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma","volume":"81","author":"Qi","year":"2011","journal-title":"Biochemical Pharmacology"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107552_bb0730","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1002\/ijc.26324","article-title":"AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas","volume":"130","author":"Qi","year":"2012","journal-title":"International Journal of Cancer"},{"issue":"9806","key":"10.1016\/j.pharmthera.2020.107552_bb0735","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0140-6736(11)61040-4","article-title":"Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): An open-label randomised phase 3 trial","volume":"378","author":"Recher","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107552_bb0740","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1158\/1078-0432.CCR-13-0580","article-title":"A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"20","author":"Ribrag","year":"2014","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107552_bb0745","first-page":"44","article-title":"MOPP\/ABV\/CAD chemotherapy with and without recombinant human granulocyte-macrophage colony stimulating factor in untreated, unfavorable prognosis Hodgkin's disease","volume":"78","author":"Riccardi","year":"1993","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107552_bb0750","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1002\/cncr.20245","article-title":"Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma","volume":"100","author":"Rizzieri","year":"2004","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.pharmthera.2020.107552_bb0755","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1002\/cncr.24359","article-title":"Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: Report of the pivotal phase 2 study","volume":"115","author":"Rodriguez","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2020.107552_bb0760","doi-asserted-by":"crossref","first-page":"46356","DOI":"10.1038\/srep46356","article-title":"Synthesis and biological evaluation of 2-methyl-4,5-disubstituted oxazoles as a novel class of highly potent Antitubulin agents","volume":"7","author":"Romagnoli","year":"2017","journal-title":"Scientific Reports"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107552_bb0765","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41416-019-0611-6","article-title":"Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: The FUJI cohort","volume":"121","author":"Rouyer","year":"2019","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2020.107552_bb0770","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1146\/annurev.med.48.1.353","article-title":"The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents","volume":"48","author":"Rowinsky","year":"1997","journal-title":"Annual Review of Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107552_bb0775","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00000421-200210000-00005","article-title":"Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer","volume":"25","author":"Saad","year":"2002","journal-title":"American Journal of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107552_bb0780","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3324\/haematol.10661","article-title":"Ifosfamide, gemcitabine, and vinorelbine: A new induction regimen for refractory and relapsed Hodgkin\u2019s lymphoma","volume":"92","author":"Santoro","year":"2007","journal-title":"Haematologica"},{"issue":"27","key":"10.1016\/j.pharmthera.2020.107552_bb0785","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1200\/JCO.2016.66.4466","article-title":"Bendamustine in combination with gemcitabine and Vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: Final results of a multicenter phase II study","volume":"34","author":"Santoro","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"5698","key":"10.1016\/j.pharmthera.2020.107552_bb0790","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/277665a0","article-title":"Promotion of microtubule assembly in vitro by taxol","volume":"277","author":"Schiff","year":"1979","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107552_bb0795","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/annonc\/mdp491","article-title":"Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors","volume":"21","author":"Schmid","year":"2010","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107552_bb0800","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab Vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107552_bb0805","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.clml.2013.05.007","article-title":"Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed\/refractory Hodgkin lymphoma","volume":"13","author":"Sinha","year":"2013","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"issue":"12 Supplement","key":"10.1016\/j.pharmthera.2020.107552_bb0810","doi-asserted-by":"crossref","first-page":"C097","DOI":"10.1158\/1535-7163.TARG-19-C097","article-title":"Abstract C097: Pyrrolo[2\u2032,3\u2032:3,4]cyclohepta[1,2-d][1,2]oxazoles: A new class of antimitotic agents","volume":"18","author":"Span\u00f2","year":"2019","journal-title":"Molecular Cancer Therapeutics"},{"issue":"15","key":"10.1016\/j.pharmthera.2020.107552_bb0815","doi-asserted-by":"crossref","first-page":"7223","DOI":"10.1021\/acs.jmedchem.6b00777","article-title":"Preclinical activity of new [1,2]Oxazolo[5,4-e]isoindole derivatives in diffuse malignant peritoneal mesothelioma","volume":"59","author":"Spano","year":"2016","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107552_bb0820","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.ejmech.2016.09.013","article-title":"[1,2]Oxazolo[5,4-e]isoindoles as promising tubulin polymerization inhibitors","volume":"124","author":"Spano","year":"2016","journal-title":"European Journal of Medicinal Chemistry"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107552_bb0825","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1158\/1078-0432.CCR-04-2291","article-title":"Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol)","volume":"11","author":"Sparreboom","year":"2005","journal-title":"Clinical Cancer Research"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107552_bb0830","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1128\/MCB.18.6.3509","article-title":"Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase","volume":"18","author":"Srivastava","year":"1998","journal-title":"Molecular and Cellular Biology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107552_bb0835","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s10637-018-0570-4","article-title":"Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: A dose-escalation, phase I study","volume":"36","author":"Stathis","year":"2018","journal-title":"Investigational New Drugs"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107552_bb0840","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1007\/s10637-014-0151-0","article-title":"Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed\/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma","volume":"32","author":"Tannir","year":"2014","journal-title":"Investigational New Drugs"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107552_bb0845","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1182\/blood-2003-12-4428","article-title":"Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107552_bb0850","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/bjh.15950","article-title":"Possibility of a risk-adapted treatment strategy for untreated aggressive adult T-cell leukaemia-lymphoma (ATL) based on the ATL prognostic index: A supplementary analysis of the JCOG9801","volume":"186","author":"Toyoda","year":"2019","journal-title":"British Journal of Haematology"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107552_bb0855","first-page":"4205","article-title":"Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma","volume":"6","author":"Vaishampayan","year":"2000","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107552_bb0860","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s12033-009-9193-5","article-title":"On and around microtubules: An overview","volume":"43","author":"Wade","year":"2009","journal-title":"Molecular Biotechnology"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107552_bb0865","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/bjc.1995.430","article-title":"Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models","volume":"72","author":"Webb","year":"1995","journal-title":"British Journal of Cancer"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107552_bb0870","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/bjh.13014","article-title":"Paclitaxel, topotecan and rituximab: Long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma","volume":"167","author":"Westin","year":"2014","journal-title":"British Journal of Haematology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107552_bb0875","doi-asserted-by":"crossref","first-page":"556","DOI":"10.4161\/mabs.27756","article-title":"Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models","volume":"6","author":"Whiteman","year":"2014","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107552_bb0880","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1517\/13543784.2015.971154","article-title":"Discontinued in 2013: Oncology drugs","volume":"24","author":"Williams","year":"2015","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107552_bb0885","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1200\/JCO.1994.12.8.1621","article-title":"Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I\/II trial of 96-hour infusion","volume":"12","author":"Wilson","year":"1994","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107552_bb0890","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1182\/blood.V99.8.2685","article-title":"Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: A pharmacodynamic approach with high efficacy","volume":"99","author":"Wilson","year":"2002","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107552_bb0895","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1182\/blood.V89.2.601","article-title":"Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin\u2019s lymphomas","volume":"89","author":"Wilson","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107552_bb0900","doi-asserted-by":"crossref","first-page":"103260","DOI":"10.1016\/j.bioorg.2019.103260","article-title":"Abstract 4589: Preclinical investigation of SGN-CD70A antibody-drug conjugate in T cell lymphomas","volume":"92","author":"Yang","year":"2019","journal-title":"Bioorg Chem."},{"key":"10.1016\/j.pharmthera.2020.107552_bb0905","doi-asserted-by":"crossref","first-page":"103260","DOI":"10.1016\/j.bioorg.2019.103260","article-title":"Novel [1,2,4]triazolo[1,5-a]pyrimidine derivatives as potent antitubulin agents: Design, multicomponent synthesis and antiproliferative activities","volume":"92","author":"Yang","year":"2019","journal-title":"Bioorganic Chemistry"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107552_bb0910","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1046\/j.1365-2141.1997.d01-2012.x","article-title":"Paclitaxel activity for the treatment of non-Hodgkin\u2019s lymphoma: Final report of a phase II trial","volume":"96","author":"Younes","year":"1997","journal-title":"British Journal of Haematology"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2020.107552_bb0915","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/annonc\/8.suppl_1.S129","article-title":"Paclitaxel (Taxol) for the treatment of lymphoma","volume":"8","author":"Younes","year":"1997","journal-title":"Annals of Oncology"},{"issue":"13","key":"10.1016\/j.pharmthera.2020.107552_bb0920","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S1470-2045(13)70501-1","article-title":"Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin\u2019s lymphoma: A phase 1, open-label, dose-escalation study","volume":"14","author":"Younes","year":"2013","journal-title":"The Lancet Oncology"},{"issue":"18","key":"10.1016\/j.pharmthera.2020.107552_bb0925","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107552_bb0930","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1023\/A:1011172215216","article-title":"Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin\u2019s lymphoma","volume":"12","author":"Younes","year":"2001","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107552_bb0935","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1046\/j.1365-2141.1998.01048.x","article-title":"Paclitaxel plus high-dose cyclophosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin\u2019s lymphoma","volume":"103","author":"Younes","year":"1998","journal-title":"British Journal of Haematology"},{"issue":"14","key":"10.1016\/j.pharmthera.2020.107552_bb0940","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1158\/1078-0432.CCR-14-2035","article-title":"A novel anti-CD22 Anthracycline-based antibody-drug conjugate (ADC) that overcomes resistance to Auristatin-based ADCs","volume":"21","author":"Yu","year":"2015","journal-title":"Clinical Cancer Research"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107552_bb0945","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/sj.bjc.6600914","article-title":"Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma","volume":"88","author":"Zekri","year":"2003","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2020.107552_bb0950","doi-asserted-by":"crossref","first-page":"43398","DOI":"10.1038\/srep43398","article-title":"Discovery and optimization of novel 5-Indolyl-7-arylimidazo[1,2-a]pyridine-8-carbonitrile derivatives as potent Antitubulin agents targeting colchicine-binding site","volume":"7","author":"Zhai","year":"2017","journal-title":"Scientific Reports"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107552_bb0955","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jconrel.2005.01.010","article-title":"Liposome-encapsulated vincristine, vinblastine and vinorelbine: A comparative study of drug loading and retention","volume":"104","author":"Zhigaltsev","year":"2005","journal-title":"Journal of Controlled Release"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107552_bb0960","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/CAD.0b013e3282f3138a","article-title":"Activation of Jun N-terminal kinase is a mediator of vincristine-induced apoptosis of melanoma cells","volume":"19","author":"Zhu","year":"2008","journal-title":"Anti-Cancer Drugs"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107552_bb0965","first-page":"287","article-title":"Efficacy of vinorelbine, epirubicin and prednisone combination regimen in pretreated elderly patients with aggressive non-Hodgkin\u2019s lymphoma","volume":"86","author":"Zinzani","year":"2001","journal-title":"Haematologica"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725820300802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725820300802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:05:04Z","timestamp":1759010704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725820300802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":193,"alternative-id":["S0163725820300802"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107552","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An overview on anti-tubulin agents for the treatment of lymphoma patients","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107552","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107552"}}